logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Phosphodiesterase 5 Inhibitor class drugs

    FiltersReset Filters
    6 results

    • adcirca

      (Tadalafil)
      United Therapeutics Corporation
      Usage: ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) (WHO Group 1) to enhance exercise capacity. It has been primarily studied in patients with NYHA Functional Class II-III symptoms, including cases of idiopathic or heritable PAH and PAH linked to connective tissue diseases.

    • cialis

      (Tadalafil)
      Eli Lilly and Company
      Usage: CIALIS is indicated for the treatment of erectile dysfunction (ED) and the symptoms of benign prostatic hyperplasia (BPH). It can also be used for patients experiencing both ED and BPH. Use with finasteride is recommended for up to 26 weeks due to diminishing benefits beyond this period.

    • revatio

      (sildenafil citrate)
      PFIZER LABORATORIES DIV PFIZER INC
      Usage: REVATIO is indicated for treating pulmonary arterial hypertension (PAH) in adults and pediatric patients aged 1 to 17 years. It aims to improve exercise ability and delay clinical worsening in adults, while in pediatrics, it also addresses pulmonary hemodynamics when standardized exercise testing isn’t feasible.

    • sildenafil

      (Sildenafil)
      Ajanta Pharma USA Inc.
      Usage: Sildenafil for oral suspension is indicated for adults with pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening. Pediatric use information exists but is not included in this drug's label due to marketing exclusivity rights.

    • tadliq

      (Tadalafil)
      CMP Pharma, Inc.
      Usage: TADLIQ® is indicated for treating pulmonary arterial hypertension (PAH) in patients with WHO Group 1 classification. It aims to improve exercise ability, primarily in those with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH linked to connective tissue diseases.

    • viagra

      (sildenafil citrate)
      PFIZER LABORATORIES DIV PFIZER INC
      Usage: VIAGRA is indicated for the treatment of erectile dysfunction, helping men achieve and maintain an erection suitable for sexual activity.